These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21185183)

  • 1. Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.
    Pettersson M; Campbell BM; Dounay AB; Gray DL; Xie L; O'Donnell CJ; Stratman NC; Zoski K; Drummond E; Bora G; Probert A; Whisman T
    Bioorg Med Chem Lett; 2011 Jan; 21(2):865-8. PubMed ID: 21185183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
    Dounay AB; Barta NS; Campbell BM; Coleman C; Collantes EM; Denny L; Dutta S; Gray DL; Hou D; Iyer R; Maiti SN; Ortwine DF; Probert A; Stratman NC; Subedi R; Whisman T; Xu W; Zoski K
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1114-7. PubMed ID: 20031410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
    Gray DL; Xu W; Campbell BM; Dounay AB; Barta N; Boroski S; Denny L; Evans L; Stratman N; Probert A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6604-7. PubMed ID: 19854053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
    Jensen NH; Rodriguiz RM; Caron MG; Wetsel WC; Rothman RB; Roth BL
    Neuropsychopharmacology; 2008 Sep; 33(10):2303-12. PubMed ID: 18059438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist.
    Li CS; Zhang L; Haske T; Dounay A; Gray D; Barta N; Brodfuehrer J; Lepsy C; Campbell B
    AAPS J; 2012 Jun; 14(2):365-76. PubMed ID: 22454087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.
    Thomas GH; Babbs AJ; Chatfield RE; Krülle TM; Widdowson PS; Provost D; McCormack JG
    Obesity (Silver Spring); 2009 Mar; 17(3):467-73. PubMed ID: 19219064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
    Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M
    J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: structure-affinity/activity relationship at alpha1-adrenoceptor subtypes and at 5-HT1A receptors.
    Franchini S; Prandi A; Baraldi A; Sorbi C; Tait A; Buccioni M; Marucci G; Cilia A; Pirona L; Fossa P; Cichero E; Brasili L
    Eur J Med Chem; 2010 Sep; 45(9):3740-51. PubMed ID: 20605276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
    Zajdel P; Subra G; Bojarski AJ; Duszyńska B; Tatarczyńska E; Nikiforuk A; Chojnacka-Wójcik E; Pawłowski M; Martinez J
    Bioorg Med Chem; 2007 Apr; 15(8):2907-19. PubMed ID: 17321139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor-genes cross-talk: effect of chronic 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin treatment on the expression of key genes in brain serotonin system and on behavior.
    Popova NK; Naumenko VS; Cybko AS; Bazovkina DV
    Neuroscience; 2010 Aug; 169(1):229-35. PubMed ID: 20423722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist.
    Picard M; Morisset S; Cloix JF; Bizot JC; Guerin M; Beneteau V; Guillaumet G; Hevor TK
    Neuroscience; 2010 Sep; 169(3):1337-46. PubMed ID: 20580787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
    Jones CA; Johnston LC; Jackson MJ; Smith LA; van Scharrenburg G; Rose S; Jenner PG; McCreary AC
    Eur Neuropsychopharmacol; 2010 Aug; 20(8):582-93. PubMed ID: 20434890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.
    Fish PV; Wakenhut F; Ryckmans T; Stobie A
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4579-83. PubMed ID: 19616432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flesinoxan challenge suggests that chronic treatment with paroxetine in rats does not desensitize receptors controlling 5-HT synthesis.
    Skelin I; Yamane F; Diksic M
    Neurochem Int; 2008 Dec; 53(6-8):236-43. PubMed ID: 18786747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.
    Fish PV; Andrews MD; Jonathan Fray M; Stobie A; Wakenhut F; Whitlock GA
    Bioorg Med Chem Lett; 2009 May; 19(10):2829-34. PubMed ID: 19359175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serotonin subtype 1A receptor regulates cortisol secretion in the Gulf toadfish, Opsanus beta.
    Medeiros LR; Mager EM; Grosell M; McDonald MD
    Gen Comp Endocrinol; 2010 Sep; 168(3):377-87. PubMed ID: 20488186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
    de Boer SF; Koolhaas JM
    Eur J Pharmacol; 2005 Dec; 526(1-3):125-39. PubMed ID: 16310183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.
    Mignon L; Wolf WA
    Psychopharmacology (Berl); 2002 Aug; 163(1):85-94. PubMed ID: 12185404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT(1A) receptor: an old target as a new attractive tool in drug discovery from central nervous system to cancer.
    Fiorino F; Severino B; Magli E; Ciano A; Caliendo G; Santagada V; Frecentese F; Perissutti E
    J Med Chem; 2014 Jun; 57(11):4407-26. PubMed ID: 24295064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding.
    Odagaki Y; Toyoshima R; Yamauchi T
    J Psychopharmacol; 2005 May; 19(3):235-41. PubMed ID: 15888508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.